Zoetis
Zoetis Inc. (NASDAQ: ZTS) is a global leader in the animal health industry with a legacy spanning nearly 75 years. The company discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health solutions. Zoetis operates… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zoetis does
In the company’s own words
Zoetis Inc. (NASDAQ: ZTS) is a global leader in the animal health industry with a legacy spanning nearly 75 years. The company discovers, develops, manufactures and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health solutions. Zoetis operates through two primary segments: the United States, which generated 54% of total revenue, and International operations, which accounted for 45% of revenue, with the remaining 1% derived from contract manufacturing services and human health products.
The company maintains a diversified portfolio across eight core animal species: dogs, cats and horses in the companion animal segment, and cattle, swine, poultry, fish and sheep in the livestock segment. Its product offerings span seven major categories including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics. Companion animal products represent approximately 70% of revenue while livestock products comprise 29%.
Zoetis operates a global manufacturing network of 21 owned or leased facilities across North America, Europe, Asia, Australia and South America, supplemented by relationships with over 90 contract manufacturing organizations. The company directly markets products in approximately 45 countries with distribution in more than 100 countries globally. As of December 31, 2025, Zoetis employed approximately 3,900 sales representatives and technical specialists, with approximately 1,700 employees dedicated to research and development operations headquartered in Kalamazoo, Michigan.
The company's intellectual property portfolio includes more than 5,500 granted patents and 1,600 pending patent applications filed across over 50 countries. Notable proprietary brands include Simparica and Simparica Trio for parasitic control, Apoquel for dermatology, Librela and Solensia for osteoarthritis pain management, and the Vetscan diagnostic platform. Zoetis was incorporated as a Delaware corporation in July 2012, following its separation from Pfizer Inc. The company's website is www.zoetis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PARSIPPANY, NJ
- Fiscal year end
- December
- CIK
- 1555280
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zoetis — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Zoetis · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Zoetis’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Zoetis’s bonds, as funds hold them
Funds report holding 11 issues of Zoetis’s debt, $1.35B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.48%, maturing 2027 to 2050.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zoetis and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zoetis's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zoetis's last four quarterly filings that the numbers alone won't show?”